Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +37.72%
#2 Versatize Coin Versatize Coin +32.51%
#3 Siren Siren +30.99%
#4 Purr Purr +28.11%
#5 Official Trump Official Trump +20.50%
#6 OriginTrail OriginTrail +17.22%
#7 Prom Prom +17.05%
#8 ApeX ApeX +16.64%
#9 UnifAI Network UnifAI Network +15.84%
#10 Pendle Pendle +14.37%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTK
Classement en actions #21736
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in... Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.
Prix de l'action
$2.23
Dernière synchronisation: 2023-09-29
Capitalisation boursière
$101.43M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Paratek Pharmaceuticals, Inc. (PRTK)

Catégorie

Healthcare
Nombre d'actions en circulation pour Paratek Pharmaceuticals, Inc. (PRTK)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Paratek Pharmaceuticals, Inc., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Paratek Pharmaceuticals, Inc. (PRTK) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH